Çocuklarda Tedavi Edilebilir Nöromusküler Hastalıklar
Özet
Çocukluk döneminde sık görülen nöromuskuler hastalıklar, genellikle kalıtsal geçişli olup ciddi motor kayıplara ve ilerleyici kas güçsüzlüğüne yol açmaktadır. Günümüzde genetik ve medikal teknolojilerdeki gelişmeler sayesinde bu hastalıkların tedavisinde hastaların yaşam kalitesini artıran önemli seçenekler sunulmaktadır. Duchenne ve Becker musküler distrofi, Spinal Musküler Atrofi ve Pompe hastalığı gibi temel tabloların yanı sıra, erken teşhis ve multidisipliner yaklaşımlar başarıyı doğrudan etkilemektedir. Doğru tedavi stratejilerinin uygulanması, hastalığın ilerlemesini yavaşlatmakta ve etkilenen çocukların yaşam beklentisini iyileştirmektedir.
Neuromuscular diseases in childhood are often hereditary, causing significant motor impairment and progressive muscle weakness. Recent advancements in medical technology and genetics have introduced promising treatment options that significantly improve the quality of life for affected patients. Conditions such as Duchenne and Becker muscular dystrophy, Spinal Muscular Atrophy, and Pompe disease benefit greatly from early diagnosis and integrated, multidisciplinary management. Implementing effective therapeutic strategies is crucial for slowing disease progression and enhancing long-term outcomes for these children.
Referanslar
Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928.
Yan J, Feng J, Buzin CH, et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). Hum Mutat. 2004;23(2):203-204.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-361.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267.
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
Bovolenta M, Neri M, Fini S, et al. A novel custom high density-comparative genomic hybridization array detects common rearrangements as well as deep intronic mutations in dystrophinopathies. BMC Genomics. 2008;9:572.
del Gaudio D, Yang Y, Boggs BA, et al. Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization. Hum Mutat. 2008;29(9):1100-1107.
Manzur AY, Kuntzer T, Pike M, Swan AV. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane database of systematic reviews. 2008(1).
Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004;14(8-9):476-482
Bello L, Gordish-Dressman H, Morgenroth LP et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015 Sep 22;85(12):1048-55.
Mendell, JR, et al, Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med, 1989. 320(24): p. 1592-7.
Griggs, RC, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol, 1991. 48(4): p. 383-8.
Gloss, D, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2016. 86(5): p. 465-72.
Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol. 2010;25(9):1158-1164.
Bell JM, Shields MD, Watters J, et al. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2017;1(1):CD010899.
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002;111(6):477-500.
Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci. 2016;3:7.
Palladino A, Passamano L, Taglia A, et al. Cardiac involvement in patients with spinal muscular atrophies. Acta Myol. 2011;30(3):175-178.
Bianco F, Pane M, D'Amico A, et al. Cardiac function in types II and III spinal muscular atrophy: should we change standards of care?. Neuropediatrics. 2015;46(1):33-36.
Pera MC, Romeo DM, Graziano A, et al. Sleep disorders in spinal muscular atrophy. Sleep Med. 2017;30:160-163.
Janoudi G, McCormack S. Nusinersen for Adolescents and Adults with Spinal Muscular Atrophy: A Review of Clinical Effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 10, 2020.
Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J Clin Med. 2020;9(7):2222
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother. 2020;54(10):1001-1009
Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2015;84(13):1369-1378.
Shieh PB. Muscular dystrophies and other genetic myopathies. Neurol Clin. 2013;31(4):1009-1029.
Yurchenco PD, McKee KK, Reinhard JR, Rüegg MA. Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018;71-72:174-187
Pozsgai ER, Griffin DA, Heller KN, Mendell JR, Rodino-Klapac LR. Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol Ther. 2017;25(4):855-869
Potter RA, Griffin DA, Sondergaard PC, et al. Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy. Hum Gene Ther. 2018;29(7):749-762.
Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002;2(2):145-166.
van der Ploeg AT, Kruijshaar ME, Toscano A, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768-e31.
Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.
Parenti G, Andria G, Valenzano KJ. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. Mol Ther. 2015;23(7):1138-1148
Miller JN, Pearce DA. Nonsense-mediated decay in genetic disease: friend or foe?. Mutat Res Rev Mutat Res. 2014;762:52-64.
van der Wal E, Bergsma AJ, Pijnenburg JM, van der Ploeg AT, Pijnappel WWMP. Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease. Mol Ther Nucleic Acids. 2017;7:90-100.
Corti M, Liberati C, Smith BK, et al. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. Hum Gene Ther Clin Dev. 2017;28(4):208-218.
Jones HR Jr. Guillain-Barré syndrome: perspectives with infants and children. Semin Pediatr Neurol. 2000;7(2):91-102.
Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barre syndrome in preschool children. Neurology. 2011;76(9):807-810.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727.
Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020;25:5-16.
Sladky JT. Neuropathy in childhood. Semin Neurol. 1987;7(1):67-75.
Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996;47(1):98-102.
Ropper AH. Current treatments for CIDP. Neurology. 2003;60(8 Suppl 3):S16-S22
Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570-3578.
Santiago RA, Silva CA, Caparbo VF, Sallum AM, Pereira RM. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol. 2008;37(1):40-47.
